October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood ...

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.

While pregnancy-associated cancer risks increased with age, breast cancer during pregnancy tended to not impact obstetric ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain ...

Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or ...

Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

Research is analyzing the effect of imtermittent fasting on quality of life outcomes in patients undergoing radiation therapy.

Overall, there were 304,951 episodes for the 127,296 unique patients with cancer, and 38.6% of the episodes and 55% of patients had narcotics prescribed.

The FDA expanded the approval of methotrexate to include patients with pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis. The FDA approval of methotrexate (Jylamvo ...